Background and study aim: Elevation of liver chemistries in COVID19  infection has been documented worldwide.  Our aim was to assess the impact of COVID19 on patients with chronic  liver  disease (CLD).
Patients and Methods:A total of 100  COVID19  patients (70 CLD patients and 30 non-CLD patients) were  enrolled in a  retrospective study to evaluate baseline and  follow-up clinical and laboratory characteristics  during 2020-2022.
Results:CLD patients had higher frequency of severe disease, ICU admission, non-invasive and mechanical ventilation and prolonged ICU stay. No significant differences between both groups regarding baseline and follow-up and clinical and laboratory data. Each group showed mild raised baseline liver enzymes and serum bilirubin levels with post-recovery improvement without statistical significance.
Conclusion:Severe infection, and prolonged hospital/ICU stay were higher in COVID19 patients with underling CLD. Monitoring of those high risk patients is a matter of worry increasing their diagnostic and therapeutic burden.